MARKET WIRECNBC • 1h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why DYN Stock advanced +0.35% Today — RQD Quant Desk Flash
$17.04 +0.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
Dyne Therapeutics Inc. (DYN) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $3.18B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DYN)Realized 20D OHLCV Swing Band: ±11.9%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DYN Stock advanced +0.35% Today — RQD Quant Desk Flash
Dyne Therapeutics Inc. (DYN) advanced +0.35% to $17.04, trading at 23% of its 52-week range ($14 – $27.31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 23% of its 52-week range ($14 – $27.31) with RSI-14 at 50 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.9% around $17.04 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live DYN Headlines & Catalysts
MARKET WIRECNBC • 2h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 3h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 4h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 5h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 6h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 6h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 6h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DYN)
- ✓Walkthrough of DYN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DYN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.91%▲ RESISTANCE BREAKOUT
2026-10-30O $16.97H $17.19L $16.34C $17.04VOL 1.45M
RES: $15.63SUP: $13.96SMA50: $18.53SMA200: $19.31
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DYN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DYN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DYN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DYN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DYN)
Health Care Rank #630 of 1016
⚔️ IDYA vs DYN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DYN vs. IDYA, TLX, ELVN, BHC)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Dyne Therapeutics Inc. (DYN) ranks #630 by composite RQD confidence (40/100, grade D-) and #202 by equity capitalization ($3.18B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with DYN at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DYN
ACTIVE
Dyne Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +0.35% | $3.18B | Benchmark Subject |
| IDYA IDEAYA Biosciences Inc. | D | 45/100 | — | — | -13.8% | -3.15% | $3.17B | /idya-vs-dyn → |
| TLX Telix Pharmaceuticals Limited | D+ | 54/100 | — | — | — | +2.70% | $3.22B | /tlx-vs-dyn → |
| ELVN Enliven Therapeutics Inc. | D- | 40/100 | — | — | -26.2% | +0.67% | $3.30B | /elvn-vs-dyn → |
| BHC Bausch Health Companies Inc. | C+ | 69/100 | 21.2x | — | 7.6% | +28.76% | $3.33B | /bhc-vs-dyn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818794In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dyne Therapeutics Inc. (DYN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$446, operating cash flow of -$403.2M, and free cash flow of -$405.1M (-37.4% YoY). On the balance sheet, DYN closed FY2025 with $1.19B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$446 | -$403.2M | -$405.1M | $1.19B | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$317 | -$292.4M | -$294.7M | $691.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$236 | -$188.2M | -$188.2M | — | — |
3. DYN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DYN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Dyne Therapeutics Inc. (NASDAQ: DYN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $17.04 (+0.35% 1D, market cap $3.18B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DYN ranks #630 in composite RQD confidence.
How does DYN compare to IDYA and TLX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DYN carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IDYA (IDEAYA Biosciences Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -13.8%, cap $3.17B) and TLX (Telix Pharmaceuticals Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $3.22B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DYN?
Per DYN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818794), Dyne Therapeutics Inc. generated $0 in revenue, -$446 in net income, and -$405.1M in free cash flow against $1.19B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DYN trading relative to its 50-day, 200-day, and 52-week technical levels?
DYN last traded at $17.04 (+0.35% on volume of 1,427,372 shares), positioning the stock -8.04% below its 50-day simple moving average ($18.53) and -11.76% below its 200-day simple moving average ($19.31). Across its 52-week range of $14.00 to $27.31, DYN sits at the 22.8% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($15.01 to $19.07).
DYN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is DYN stock moving today?
Why DYN Stock advanced +0.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.